Literature DB >> 26034374

Self-medication of achalasia with cannabis, complicated by a cannabis use disorder.

Amandine Luquiens1, Nelson Lourenco1, Amine Benyamina1, Henri-Jean Aubin1.   

Abstract

Achalasia is a rare esophagus motility disorder. Medical, endoscopic and surgical treatments are available, but all endorse high relapse rates. No data has been published to date reporting a therapeutic effect of cannabis use neither in achalasia nor on its influence on manometric measurements. We report the case of a patient diagnosed with achalasia. He could benefit from a large panel of therapeutic interventions, but none of them was effective over the time. He first used cannabis at age 20 and identified benefits regarding achalasia symptoms. He maintained regular moderate cannabis use for 9 years, with minimal digestive inconvenience. A manometry performed without cannabis premedication was realized at age 26 and still found a cardiospasm. Cannabis use could explain the gap between functional symptoms assessment and manometry measurement. Further investigations are warranted to explore a therapeutic effect of cannabis in achalasia and possible influence on outcome measurements.

Entities:  

Keywords:  Achalasia; Addiction; Cannabis; Manometry; Treatment

Mesh:

Year:  2015        PMID: 26034374      PMCID: PMC4445116          DOI: 10.3748/wjg.v21.i20.6381

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

Review 1.  The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.

Authors:  David Baker; Gareth Pryce; Samuel J Jackson; Chris Bolton; Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2012-01-18       Impact factor: 4.339

Review 2.  Cannabis and its derivatives: review of medical use.

Authors:  Lawrence Leung
Journal:  J Am Board Fam Med       Date:  2011 Jul-Aug       Impact factor: 2.657

3.  A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.

Authors:  Kerri Alexandra Schoedel; Nancy Chen; Annie Hilliard; Linda White; Colin Stott; Ethan Russo; Stephen Wright; Geoffrey Guy; Myroslava K Romach; Edward M Sellers
Journal:  Hum Psychopharmacol       Date:  2011-04       Impact factor: 1.672

4.  Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.

Authors:  Carl L Hart; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

5.  Advances in the treatment of achalasia.

Authors:  Jeffrey A Blatnik; Jeffrey L Ponsky
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

Review 6.  Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Authors:  Yahiya Y Syed; Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

7.  Assessing bolus retention in achalasia using high-resolution manometry with impedance: a comparator study with timed barium esophagram.

Authors:  Yu K Cho; Anna M Lipowska; Frédéric Nicodème; Ezra N Teitelbaum; Eric S Hungness; Elyse R Johnston; Andrew Gawron; Peter J Kahrilas; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2014-04-08       Impact factor: 10.864

8.  2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling.

Authors:  Judy Y Su; Anhkiet C Vo
Journal:  Eur J Pharmacol       Date:  2007-01-16       Impact factor: 4.432

Review 9.  The therapeutic potential of cannabis and cannabinoids.

Authors:  Franjo Grotenhermen; Kirsten Müller-Vahl
Journal:  Dtsch Arztebl Int       Date:  2012-07-23       Impact factor: 5.594

10.  Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

Authors:  Jody Corey-Bloom; Tanya Wolfson; Anthony Gamst; Shelia Jin; Thomas D Marcotte; Heather Bentley; Ben Gouaux
Journal:  CMAJ       Date:  2012-05-14       Impact factor: 8.262

View more
  1 in total

Review 1.  Review: The Role of Cannabinoids on Esophageal Function-What We Know Thus Far.

Authors:  Jonathan Gotfried; Rahul Kataria; Ron Schey
Journal:  Cannabis Cannabinoid Res       Date:  2017-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.